Literature DB >> 8441404

Conservation of transcriptional activation functions of the NF-kappa B p50 and p65 subunits in mammalian cells and Saccharomyces cerevisiae.

P A Moore1, S M Ruben, C A Rosen.   

Abstract

The NF-kappa B transcription factor complex is composed of a 50-kDa (p50) and a 65-kDa (p65) subunit. Both subunits bind to similar DNA motifs and elicit transcriptional activation as either homo- or heterodimers. By using chimeric proteins that contain the DNA binding domain of the yeast transcriptional activator GAL4 and subdomains of p65, three distinct transcriptional activation domains were identified. One domain was localized to a region of 42 amino acids containing a potential leucin zipper structure, consistent with earlier reports. Two other domains, both acidic and rich in prolines, were also identified. Of perhaps more significance, the same minimal activation domains that were functional in mammalian cells were also functional in the yeast Saccharomyces cerevisiae. Coexpression of the NF-kappa B inhibitory molecule, I kappa B, reduced the transcriptional activity of p65 significantly, suggesting the ability of I kappa B to function in a similar manner in S. cerevisiae. Surprisingly, while the conserved rel homology domain of p65 demonstrated no transcriptional activity in either mammalian cells or S. cerevisiae, the corresponding domain in p50 was a strong transcriptional activator in S. cerevisiae. The observation that similar domains elicit transcriptional activation in mammalian cells and S. cerevisiae demonstrates strong conservation of the transcriptional machinery required for NF-kappa B function and provides a powerful genetic system to study the transcriptional mechanisms of these proteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8441404      PMCID: PMC359479          DOI: 10.1128/mcb.13.3.1666-1674.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  76 in total

1.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences.

Authors:  R Sen; D Baltimore
Journal:  Cell       Date:  1986-08-29       Impact factor: 41.582

2.  Saturation mutagenesis of the yeast his3 regulatory site: requirements for transcriptional induction and for binding by GCN4 activator protein.

Authors:  D E Hill; I A Hope; J P Macke; K Struhl
Journal:  Science       Date:  1986-10-24       Impact factor: 47.728

3.  Genetic isolation of ADA2: a potential transcriptional adaptor required for function of certain acidic activation domains.

Authors:  S L Berger; B Piña; N Silverman; G A Marcus; J Agapite; J L Regier; S J Triezenberg; L Guarente
Journal:  Cell       Date:  1992-07-24       Impact factor: 41.582

4.  Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B.

Authors:  S Ghosh; D Baltimore
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

5.  NF-kappa B subunit regulation in nontransformed CD4+ T lymphocytes.

Authors:  S M Kang; A C Tran; M Grilli; M J Lenardo
Journal:  Science       Date:  1992-06-05       Impact factor: 47.728

6.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

7.  I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention.

Authors:  A A Beg; S M Ruben; R I Scheinman; S Haskill; C A Rosen; A S Baldwin
Journal:  Genes Dev       Date:  1992-10       Impact factor: 11.361

8.  Transformation of intact yeast cells treated with alkali cations.

Authors:  H Ito; Y Fukuda; K Murata; A Kimura
Journal:  J Bacteriol       Date:  1983-01       Impact factor: 3.490

9.  Factors affecting heterologous gene expression in Saccharomyces cerevisiae.

Authors:  J Mellor; M J Dobson; N A Roberts; A J Kingsman; S M Kingsman
Journal:  Gene       Date:  1985       Impact factor: 3.688

10.  The NF-kappa B p50 precursor, p105, contains an internal I kappa B-like inhibitor that preferentially inhibits p50.

Authors:  H C Liou; G P Nolan; S Ghosh; T Fujita; D Baltimore
Journal:  EMBO J       Date:  1992-08       Impact factor: 11.598

View more
  24 in total

1.  A general strategy to enhance the potency of chimeric transcriptional activators.

Authors:  S Natesan; E Molinari; V M Rivera; R J Rickles; M Gilman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  A new method for the selection of protein interactions in mammalian cells.

Authors:  E Rojo-Niersbach; D Morley; S Heck; N Lehming
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

3.  Conserved interaction of the papillomavirus E2 transcriptional activator proteins with human and yeast TFIIB proteins.

Authors:  J D Benson; R Lawande; P M Howley
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  In vivo binding of NF-kappaB to the IkappaBbeta promoter is insufficient for transcriptional activation.

Authors:  Bryan D Griffin; Paul N Moynagh
Journal:  Biochem J       Date:  2006-11-15       Impact factor: 3.857

5.  Involvement of TFIID and USA components in transcriptional activation of the human immunodeficiency virus promoter by NF-kappaB and Sp1.

Authors:  M Guermah; S Malik; R G Roeder
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

6.  Interactions of a Rel protein with its inhibitor.

Authors:  N Lehming; S McGuire; J M Brickman; M Ptashne
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

7.  TAFII105 mediates activation of anti-apoptotic genes by NF-kappaB.

Authors:  A Yamit-Hezi; R Dikstein
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

8.  Acquisition of NFKB1-selective DNA binding by substitution of four amino acid residues from NFKB1 into RelA.

Authors:  T A Coleman; C Kunsch; M Maher; S M Ruben; C A Rosen
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

9.  Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.

Authors:  Stephanie L Nott; Yanfang Huang; Aja Kalkanoglu; Kathryn Harper; Ming Chen; Scott F Paoni; Bruce M Fenton; Mesut Muyan
Journal:  Mol Med       Date:  2009-11-17       Impact factor: 6.354

10.  Comparing regions of the Epstein-Barr virus ZEBRA protein which function as transcriptional activating sequences in Saccharomyces cerevisiae and in B cells.

Authors:  G Miller; H Himmelfarb; L Heston; J Countryman; L Gradoville; R Baumann; T Chi; M Carey
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.